Back to News
Market Impact: 0.2
Onkos Surgical® expands access to NanoCept® Antibacterial Technology for patients requiring total femoral replacement
Source: PR Newswire
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Onkos Surgical announced the market release of its ELEOS Total Femoral Adapter featuring NanoCept antibacterial technology. The launch expands NanoCept availability for patients undergoing complex, high-risk total femoral procedures, potentially strengthening Onkos Surgical's orthopedic oncology product offering. No financial contribution, regulatory milestone, or sales outlook was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
More News
- Asian stocks rise as oil retreat eases inflation fears, BOJ in focus
- Microsoft exec called AI scraping the “largest theft of labor in human history”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- After being sidelined, Boeing's Starliner to get starring role in NASA's spaceflight plans
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle